SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 158894.
  • 2
    Koizumi M, Maeda H, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer 1997; 75: 16014.
  • 3
    Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, Noma H, Kumazawa J. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 1999; 39: 17.
  • 4
    Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82: 85864.
  • 5
    Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001; 87: 34851.
  • 6
    Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001; 19: 4551.
  • 7
    de la Piedra C, Castro-Errecaborde NA, Traba ML, Mendez-Davila C, Garcia-Moreno C, Rodriguez DA, Rodriguez-Molina J. Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 2003; 331: 4553.
  • 8
    Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001; 7: 297783.
  • 9
    Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer 2003; 97: 8749.
  • 10
    Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 123544.
  • 11
    Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57: 6116.
  • 12
    Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003; 61: 9938.
  • 13
    Jung K, Lein M, v.Hösslin K, Brux B, Schnorr D, Loening SA, Sinha P. Osteoprotegerin in serum as novel marker of bone metastatic spread in prostate cancer. Clin Chem 2001; 47: 20613.
  • 14
    Sobin LH, Wittekind C. TNM classification of malignant tumours, 5th ed. New York: Wiley-Liss, 1997. 1713.
  • 15
    Broyles DL, Nielsen RG, Bussett EM, Lu WD, Mizrahi IA, Nunnelly PA, Ngo TA, Noell J, Christenson RH, Kress BC. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 1998; 44: 213947.
  • 16
    Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R, Armbruster FP. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem 1997; 43: 207682.
  • 17
    Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H, Moriguchi A, Nishizawa Y. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 2001; 47: 14104.
  • 18
    Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997; 43: 205863.
  • 19
    Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Vaananen HK. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001; 47: 597600.
  • 20
    Jung K, Lein M, von Hösslin K, Grosse A, Roth S, Possinger K, Lüftner D. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. Int J Biol Markers 2002; 17: 17781.
  • 21
    Solberg HE. Approved recommendations (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determinations of reference limits. J Clin Chem Clin Biochem 1987; 25: 64556.
  • 22
    O'Sullivan JM, Cook GJ. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46: 1529.
  • 23
    Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta 2001; 313: 95105.
  • 24
    Plebani M, Bernardi D, Meneghetti MF, Ujka F, Zaninotto M. Biological variability in assessing the clinical value of biochemical markers of bone turnover. Clin Chim Acta 2000; 299: 7786.
  • 25
    Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000; 11(Suppl 6): S3044.
  • 26
    Schober EA, Breusch SJ, Schneider U. Instability and variability of urinary telopeptides and free crosslinks. Clin Chim Acta 2002; 324: 739.
  • 27
    Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999; 14: 792801.
  • 28
    Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997; 30: 57393.
  • 29
    Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, Vessella RL. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20: 17180.
  • 30
    Morote J, M'Hammed YI, Martinez E, Esquena S, Lorente JA, Gelabert A. Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer. Urology 2002; 59: 27780.
  • 31
    Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 15616.
  • 32
    Diaz-Martin MA, Traba ML, de la Piedra C, Guerrero R, Mendez-Davila C, De La Pena EG. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 1999; 59: 12532.
  • 33
    Koizumi M, Yonese J, Fukui I, Ogata E. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 2002; 167: 18636.
  • 34
    Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 133745.
  • 35
    Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001; 47: 7480.
  • 36
    Halleen JM. Tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Anticancer Res 2003; 23: 10279.
  • 37
    Shaarawy M, Hasan M. Serum bone sialoprotein: a marker of bone resorption in postmenopausal osteoporosis. Scand J Clin Lab Invest 2001; 61: 51321.
  • 38
    Waltregny D, Bellahcene A, Van RI, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998; 90: 10008.
  • 39
    Carlinfante G, Vassilioul D, Svensson O, Wendel M, Heinegard D, Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003; 20: 43744.
  • 40
    Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 40606.
  • 41
    Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62: 161923.
  • 42
    Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells–osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9: 258797.
  • 43
    Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 230610.
  • 44
    Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin—clinical relevance and potential applications. Eur J Endocrinol 2001; 145: 6813.
  • 45
    Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 22934.
  • 46
    Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Munoz-Gomez J, Ballesta AM. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003; 48: 8248.
  • 47
    Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195202.
  • 48
    Ernst DS, Hanson J, Venner PM. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 1991; 146: 3726.
  • 49
    Kylmälä T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71: 10614.
  • 50
    Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade. Prostate 1999; 38: 2834.
  • 51
    Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999; 5: 39149.
  • 52
    Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003; 63: 2096102.
  • 53
    Eaton CL, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 2003; 29: 18998.
  • 54
    Voelkel-Johnson C. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther 2003; 2: 28390.
  • 55
    Sandler HM, Narayan S, Smith DC. Combined modality treatment for prostate cancer: role of chemotherapy. Semin Oncol 2003; 30: 95100.